Journal
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
Volume 26, Issue 4, Pages 409-416Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-2005-916156
Keywords
pulmonary arterial hypertension; prognosis; epoprostenol
Categories
Ask authors/readers for more resources
Pulmonary arterial hypertension (PAH) is a progressive arteriopathy of the pulmonary circulation that can affect a wide group of patients. Presentation and natural history of PAH are intimately linked to progressive right ventricular failure. Historically, survival in PAH has been poor, especially for patients with PAH associated with progressive systemic sclerosis and human immunodeficiency virus. Oral, subcutaneous, and intravenous therapies that have emerged during the last decade can improve symptoms and hemodynamics. This review explores the impact of these therapies on prognosis in PAH, which ultimately rests on the ability to reverse the pulmonary arteriopathy and preserve right ventricular function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available